vs
Apellis Pharmaceuticals, Inc.（APLS）与WORLD ACCEPTANCE CORP（WRLD）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是WORLD ACCEPTANCE CORP的1.4倍（$199.9M vs $141.3M），WORLD ACCEPTANCE CORP净利率更高（-0.6% vs -29.5%，领先28.8%），WORLD ACCEPTANCE CORP同比增速更快（1.9% vs -5.9%），WORLD ACCEPTANCE CORP自由现金流更多（$57.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -5.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
本公司是一家汽车金融企业，主营汽车贷款及相关金融产品，业务通过全国合作经销商网络开展。目前公司运营两大核心业务项目，分别为投资组合项目与收购项目，通过这两个项目，公司可向汽车经销商预先提供资金，以此获得底层消费贷款的服务权等相关权益。
APLS vs WRLD — 直观对比
营收规模更大
APLS
是对方的1.4倍
$141.3M
营收增速更快
WRLD
高出7.8%
-5.9%
净利率更高
WRLD
高出28.8%
-29.5%
自由现金流更多
WRLD
多$71.4M
$-14.3M
两年增速更快
APLS
近两年复合增速
-5.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $141.3M |
| 净利润 | $-59.0M | $-911.3K |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -0.7% |
| 净利率 | -29.5% | -0.6% |
| 营收同比 | -5.9% | 1.9% |
| 净利润同比 | -62.2% | -106.8% |
| 每股收益（稀释后） | $-0.40 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWRLD
| Q4 25 | $199.9M | $141.3M | ||
| Q3 25 | $458.6M | $134.5M | ||
| Q2 25 | $178.5M | $132.5M | ||
| Q1 25 | $166.8M | $165.3M | ||
| Q4 24 | $212.5M | $138.6M | ||
| Q3 24 | $196.8M | $131.4M | ||
| Q2 24 | $199.7M | $129.5M | ||
| Q1 24 | $172.3M | $159.3M |
净利润APLSWRLD
| Q4 25 | $-59.0M | $-911.3K | ||
| Q3 25 | $215.7M | $-1.9M | ||
| Q2 25 | $-42.2M | $1.3M | ||
| Q1 25 | $-92.2M | $44.3M | ||
| Q4 24 | $-36.4M | $13.4M | ||
| Q3 24 | $-57.4M | $22.1M | ||
| Q2 24 | $-37.7M | $9.9M | ||
| Q1 24 | $-66.4M | $35.1M |
营业利润率APLSWRLD
| Q4 25 | -25.6% | -0.7% | ||
| Q3 25 | 48.7% | -1.3% | ||
| Q2 25 | -18.6% | 1.5% | ||
| Q1 25 | -50.0% | 33.3% | ||
| Q4 24 | -12.3% | 11.6% | ||
| Q3 24 | -24.0% | 21.3% | ||
| Q2 24 | -14.7% | 10.0% | ||
| Q1 24 | -36.0% | 29.3% |
净利率APLSWRLD
| Q4 25 | -29.5% | -0.6% | ||
| Q3 25 | 47.0% | -1.4% | ||
| Q2 25 | -23.6% | 1.0% | ||
| Q1 25 | -55.3% | 26.8% | ||
| Q4 24 | -17.1% | 9.7% | ||
| Q3 24 | -29.2% | 16.8% | ||
| Q2 24 | -18.9% | 7.7% | ||
| Q1 24 | -38.5% | 22.0% |
每股收益（稀释后）APLSWRLD
| Q4 25 | $-0.40 | $-0.19 | ||
| Q3 25 | $1.67 | $-0.38 | ||
| Q2 25 | $-0.33 | $0.25 | ||
| Q1 25 | $-0.74 | $8.07 | ||
| Q4 24 | $-0.30 | $2.45 | ||
| Q3 24 | $-0.46 | $3.99 | ||
| Q2 24 | $-0.30 | $1.79 | ||
| Q1 24 | $-0.54 | $6.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $10.0M |
| 总债务越低越好 | — | $677.2M |
| 股东权益账面价值 | $370.1M | $351.6M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | 1.93× |
8季度趋势，按日历期对齐
现金及短期投资APLSWRLD
| Q4 25 | $466.2M | $10.0M | ||
| Q3 25 | $479.2M | $14.9M | ||
| Q2 25 | $370.0M | $8.1M | ||
| Q1 25 | $358.4M | $4.7M | ||
| Q4 24 | $411.3M | $10.3M | ||
| Q3 24 | $396.9M | $9.7M | ||
| Q2 24 | $360.1M | $11.1M | ||
| Q1 24 | $325.9M | $5.2M |
总债务APLSWRLD
| Q4 25 | — | $677.2M | ||
| Q3 25 | — | $584.6M | ||
| Q2 25 | — | $472.5M | ||
| Q1 25 | — | $447.9M | ||
| Q4 24 | — | $561.2M | ||
| Q3 24 | — | $506.6M | ||
| Q2 24 | — | $494.7M | ||
| Q1 24 | $93.1M | $498.4M |
股东权益APLSWRLD
| Q4 25 | $370.1M | $351.6M | ||
| Q3 25 | $401.2M | $365.6M | ||
| Q2 25 | $156.3M | $427.9M | ||
| Q1 25 | $164.2M | $439.5M | ||
| Q4 24 | $228.5M | $428.2M | ||
| Q3 24 | $237.1M | $417.5M | ||
| Q2 24 | $264.3M | $422.6M | ||
| Q1 24 | $266.7M | $424.4M |
总资产APLSWRLD
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.0B | ||
| Q1 25 | $807.3M | $1.0B | ||
| Q4 24 | $885.1M | $1.1B | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.0B | ||
| Q1 24 | $831.9M | $1.1B |
负债/权益比APLSWRLD
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 1.60× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | 0.35× | 1.17× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $58.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $57.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 40.5% |
| 资本支出强度资本支出/营收 | 0.1% | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $412.5M |
8季度趋势，按日历期对齐
经营现金流APLSWRLD
| Q4 25 | $-14.2M | $58.0M | ||
| Q3 25 | $108.5M | $48.6M | ||
| Q2 25 | $4.4M | $58.2M | ||
| Q1 25 | $-53.4M | $254.2M | ||
| Q4 24 | $19.4M | $61.1M | ||
| Q3 24 | $34.1M | $53.8M | ||
| Q2 24 | $-8.3M | $48.4M | ||
| Q1 24 | $-133.0M | $265.8M |
自由现金流APLSWRLD
| Q4 25 | $-14.3M | $57.2M | ||
| Q3 25 | $108.3M | $47.7M | ||
| Q2 25 | $4.4M | $57.1M | ||
| Q1 25 | $-53.4M | $250.5M | ||
| Q4 24 | $19.3M | $60.4M | ||
| Q3 24 | — | $52.7M | ||
| Q2 24 | $-8.4M | $47.3M | ||
| Q1 24 | $-133.3M | $259.9M |
自由现金流率APLSWRLD
| Q4 25 | -7.1% | 40.5% | ||
| Q3 25 | 23.6% | 35.5% | ||
| Q2 25 | 2.5% | 43.1% | ||
| Q1 25 | -32.0% | 151.6% | ||
| Q4 24 | 9.1% | 43.6% | ||
| Q3 24 | — | 40.1% | ||
| Q2 24 | -4.2% | 36.5% | ||
| Q1 24 | -77.3% | 163.2% |
资本支出强度APLSWRLD
| Q4 25 | 0.1% | 0.6% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 0.8% | ||
| Q1 24 | 0.2% | 3.7% |
现金转化率APLSWRLD
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 43.27× | ||
| Q1 25 | — | 5.74× | ||
| Q4 24 | — | 4.56× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 4.87× | ||
| Q1 24 | — | 7.58× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WRLD
暂无分部数据
